Mass High Tech honors ENS Chief Scientific Officer at Third Annual ''Women to Watch'' Award; Regina Valluzzi, PhD, Recognized
The award was announced this week at Mass High Tech's "Women to Watch 2006 Awards" in Boston. Dr. Valluzzi was recognized as exemplifying the best and brightest among women at the highest level of technology businesses in New England.
“We're proud to be able to provide a forum to recognize such notable talent within our technology community”
ENS, co-founded by Dr. Valluzzi, is a Cambridge-based company using nanotechnology to revolutionize chiral separations. Using a patented nanotechnology, the company's HPLC Chiral Columns enable previously unattainable molecular separations by offering unprecedented selectivity and scalability, and dramatically simplifying the research and analysis process. ENS's forthcoming product line is highly effective at separating a broad spectrum of chiral chemical compounds, including both large and small molecules. It promises to remove much of the current trial and error in chiral separations.
Chiral separations are processes which separate mirror-image molecules. These processes are particularly important in drug development and clinical trials , because one mirror image is often therapeutic or beneficial, while the other can produce unwanted side effects. Most of the top-selling drugs in the world are chiral, including Lipitor(R), Nexium(R) and Viagra(R), and already more than 50 percent of current drug sales are from chiral drugs.
"We're proud to be able to provide a forum to recognize such notable talent within our technology community," said Michael Olivieri, Mass High Tech publisher. "These women are examples of just how vibrant this region is when it comes to talent, commitment and devotion to innovation."
Dr. Valluzzi is the Chief Scientific Officer and the inventor of ENS' proprietary technology. While researching polymer structure and processing at Tufts, she discovered various novel routes to high surface area and nanostructured polymeric materials, which led to the creation of ENS.
About Evolved Nanomaterial Sciences (ENS)
Headquartered in Cambridge, MA, ENS utilizes patented nanotechnology to enable previously unattainable molecular separations, offering unprecedented selectivity and dramatically simplifying the drug discovery and scale-up process. ENS' web site is www.ensbio.com.